Description
Currently in clinical trials for colorectal cancer (CRC), NNS309 is being evaluated as a potential new treatment option for patients who have progressed on standard therapies. Its efficacy and safety are still under investigation, with preliminary data suggesting promising activity against certain subtypes of CRC.
Mechanism of Action
NNS309 is an experimental agent that targets a specific signaling pathway implicated in colorectal cancer progression and metastasis, potentially inhibiting tumor growth by blocking key oncogenic drivers.
Side Effects
Fatigue; Nausea; Diarrhea; Hematological toxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07261631
Phase 1
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Canada, Denmark, France, Germany, Israel, Singapore
NCT07630961
Phase 1
Not yet recruiting
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors